相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
Jonathan Zalevsky et al.
BLOOD (2009)
Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40
E. Oflazoglu et al.
BRITISH JOURNAL OF CANCER (2009)
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
Jorge Castillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Mohammad Luqman et al.
BLOOD (2008)
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
Holly M. Horton et al.
CANCER RESEARCH (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Optimizing engagement of the immune system by anti-timor antibodies: an engineer's perspective
John R. Desjarlais et al.
DRUG DISCOVERY TODAY (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
Julie A. McEarchern et al.
BLOOD (2007)
A molecular immunology approach to antibody humanization and functional optimization
Greg A. Lazar et al.
MOLECULAR IMMUNOLOGY (2007)
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
Michelle A. Fanale et al.
DRUGS (2007)
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
Thomas F. Tedder et al.
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates
Sean K. Kelley et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40
CL Law et al.
CANCER RESEARCH (2005)
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
JA Bowles et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
YT Tai et al.
CANCER RESEARCH (2005)
Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia
SP Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications
YT Tai et al.
CANCER RESEARCH (2004)
Monoclonal antibodies in the treatment of chronic lymphoid leukemias
T Robak
LEUKEMIA & LYMPHOMA (2004)
The role of the CD40 pathway in the pathogenesis and treatment of cancer
AG Eliopoulos et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
Bexxar((R)): Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma
JM Vose
ONCOLOGIST (2004)
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
GA Kennedy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation:: induction of bax
JL Szocinski et al.
BLOOD (2002)
CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity
GJD van Mierlo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells
JG Turner et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
